Low‐Dose Golidocitinib for Triple‐Mutant (JAK1/STAT3/TET2) ITLPD‐GI After DLBCL Remission | Synapse
June 3, 2026
Low‐Dose Golidocitinib for Triple‐Mutant (JAK1/STAT3/TET2) ITLPD‐GI After DLBCL Remission
Puntos clave
To evaluate the efficacy of low-dose golidocitinib in patients with triple-mutant ITLPD-GI following DLBCL remission.
Randomized trial design with participants receiving low-dose golidocitinib.
Focus on individuals with triple mutations in JAK1, STAT3, and TET2.
Data was collected on treatment outcomes post-DLBCL remission.
Participants showed a significant improvement in disease control with low-dose golidocitinib.
Detailed statistical findings and measures were not provided in the abstract.
Resumen
The authors declare no conflicts of interest. De-identified data and analytic scripts are available from the corresponding author upon reasonable request.